Status:
UNKNOWN
Exploration of the Relationship Between Inflammation and Integrity of the Blood-Brain Barrier in Suicidal Behaviour
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Depression
Eligibility:
All Genders
18-55 years
Phase:
NA
Brief Summary
Recent studies have revealed an association between history of suicide attempt and inflammatory markers in both the cerebrospinal fluid and the plasma. Post mortem studies have shown an increase in mi...
Detailed Description
105 participants will be recruited : * 35 depressed patients having attempted suicide (maximum 3 attempts in life) * 35 depressed patients without history of suicide attempt (affective controls) * 35...
Eligibility Criteria
Inclusion
- 18-55 years old
- Able to understand nature, aims, and methodology of the study
- Depending on the population :
- Current depressive episode (according to DSM-5 criteria) with a recent suicide attempt (within the 8 days before inclusion) and no more than 3 attempts in life
- Current depressive episode (according to DSM-5 criteria) without suicide attempt
- No psychiatric history (according to DSM-5 criteria)
Exclusion
- Inflammatory diseases or intercurrent infections, or chronic diseases such as hepatitis C or B, HIV, Alzheimer's, cancer or autoimmune disease
- Current antibiotic or anti-inflammatory treatments
- Refusal to participate
- Lifetime Schizoaffective disorder or schizophrenia
- On protective measures (guardianship or trusteeship)
- Deprived of liberty subject (administrative decision)
- In exclusion period for another protocol
- Not affiliated to a social security agency
- Unable to understand and/or answer a questionnaire
- Pregnant or lactating women
Key Trial Info
Start Date :
November 7 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
105 Patients enrolled
Trial Details
Trial ID
NCT04137458
Start Date
November 7 2019
End Date
July 1 2022
Last Update
October 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University hospital
Montpellier, France, 34295